That admission is what some in the field call recursive self-improvement (RSI), the point at which large language models ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that ...

Building a model capable of RSI would require automating a range of specialist tasks currently carried out by humans. At present data scientists work on the theory of AI and coders put it into ...

Abstract: JavaScript has significantly evolved, broadening its capabilities. However, the uptake of tail call optimization (TCO) remains limited, largely due to concerns about debugging difficulties ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Even as leading AI providers like OpenAI and Anthropic battle over the compute to train and release ever larger, more powerful models, other labs are going in a different direction — pursuing the ...

Good afternoon. My name is Christa, and I will be your conference operator today. At this time, I would like to welcome everyone to Meta's First Quarter 2026 Earnings Conference Call. [Operator ...

SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...